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OBJECTIVES The purpose of this study was to examine the long-term clinical outcome after percutaneous
intervention of saphenous vein grafts (SVG) and to identify the predictors of major adverse
cardiac events (MACE).
BACKGROUND Percutaneous interventions of SVGs have been associated with more procedural complica-
tions and higher restenosis rates compared with interventions on native vessels.
METHODS From 1993 to 1997, 1,062 patients underwent percutaneous intervention on 1,142 SVG
lesions. Procedural, in-hospital and long-term clinical outcomes were recorded in a database
and analyzed.
RESULTS In-hospital MACE occurred in 137 patients (13%) including death (8%), Q-wave myocardial
infarction (MI) (2%) and coronary artery bypass surgery (3%). Late MACE occurred in 565
patients (54%) including death (9%), Q-wave MI (9%) and target vessel revascularization
(36%). Any MACE occurred in 457 (43%) patients. Follow-up was available in 1,056 (99%)
patients at 3 6 1 year. Univariate predictors were restenotic lesion (odds ratio [OR]: 2.47,
confidence interval [CI]: 1.13 to 3.85, p 5 0.0003), unstable angina (OR: 1.99, CI: 1.27 to
2.91, p 5 0.04) and congestive heart failure (CHF) (OR: 1.97, CI: 1.14 to 3.24, p 5 0.02)
for in-hospital MACE, and peripheral vascular disease (PVD) (OR: 2.18, CI: 1.34 to 3.44,
p 5 0.002), intra-aortic balloon pump placement (OR: 2.08, CI: 1.13 to 3.85, p 5 0.02) and
previous MI (OR: 1.97, CI: 1.14 to 3.25, p 5 0.007) for late MACE. Independent
multivariate predictors for late MACE were restenotic lesion (relative risk [RR] 1.33, p 5
0.02), PVD (RR: 1.31, p 5 0.01), CHF (RR: 1.42, p 5 0.01) and multiple stents (RR: 1.47,
p 5 0.004). Angiographic follow-up was available for 422 patients. Angiographic restenosis
occurred in 122 (29%) of stented SVGs and 181 (43%) of nonstented SVGs (p 5 0.04). Stent
implantation did not confer a survival benefit.
CONCLUSIONS Despite the use of new interventional devices, SVG interventions are associated with
significant morbidity and mortality; SVG stenting is not associated with better three-year
event-free survival. This may be due to progressive disease at nonstented sites. (J Am Coll
Cardiol 2001;38:659–65) © 2001 by the American College of Cardiology
Coronary artery bypass graft surgery (CABG) provides
symptomatic benefit for patients with ischemic heart disease
and may prolong life in selected patients (1,2). Recurrent
angina occurs in 5% to 10% of patients per year, primarily
due to saphenous vein graft (SVG) failure. The probability
of graft degeneration increases with time and, by 10 years
after CABG, approximately 50% of SVGs are occluded and
up to 40% of patent SVGs have significant stenoses (3,4).
Repeat CABG is feasible but is associated with more
morbidity and mortality and less symptomatic improvement
compared with the initial operation (5–7).
Compared with percutaneous transluminal coronary an-
gioplasty (PTCA) of native coronary vessels, PTCA of
SVG lesions is associated with less favorable immediate
results, more adverse in-hospital events and lower event-free
survival (8). Restenosis is more frequent in SVGs than it is
in native vessels, particularly in older grafts and in stenoses
involving the aortic ostium or graft body (8). Although
stents have been shown to decrease restenosis and improve
the safety and outcome of PTCA in native vessels, they have
not been consistently shown to do so after SVG interven-
tions. We reported the immediate and long-term clinical
outcome in a series of 1,062 patients who underwent 1,142
SVG interventions in our institution.
METHODS
Patients. Between September 1993 and June 1997, percu-
taneous intervention was performed on 1,142 SVG lesions
in 1,062 patients, representing 9% of the 12,265 coronary
interventions performed in our institution. All patients were
selected for treatment on the basis of spontaneous angina or
provocable ischemia documented by noninvasive testing.
Procedures. Selection of devices was left to operator dis-
cretion and evolved during the course of the study. Inter-
ventional devices included PTCA alone on 483 lesions
(42%), extraction atherectomy on 91 lesions (8%), direc-
tional atherectomy on 46 lesions (4%), rotational atherec-
tomy on 34 lesions (3%) and excimer laser on 10 lesions
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(0.9%) according to techniques that have been previously
described (9–12). Stenting was performed after pretreat-
ment with PTCA (396 lesions [35%]) or another device (82
lesions [7%]) and was followed by high pressure adjunctive
PTCA (after 1994). Prophylactic intra-aortic balloon pump
(IABP) was used at the discretion of the operator. During
the procedure, all patients received intravenous heparin to
maintain an activated clotting time .300 s. No patients
received abciximab. No-reflow was treated with intragraft
administration of verapamil (500 mg) and nitroglycerin
(250 mg). Creatine kinase levels were routinely obtained
12 h to 18 h after the intervention. All patients who received
a stent were treated with aspirin, heparin, dextran and
coumadin (1991 to 1994) or aspirin and ticlopidine for four
weeks (after 1994).
Data collection and follow-up. Angiographic results and
in-hospital outcome were prospectively entered into a ded-
icated interventional cardiology database. Clinical follow-up
was obtained by telephone interviews with the patient or
family and by review of medical records. Mean follow-up
after three years (range one to four years) was available for
1,056 patients (99%).
End points and definitions. The primary end points of
this study were in-hospital and late major adverse cardiac
events (MACE), defined as death, Q-wave myocardial
infarction (MI) and the need for repeat revascularization by
redo-CABG or repeat percutaneous intervention. Second-
ary end points included in-hospital angiographic complica-
tions, including no-reflow (defined as Thrombolysis In
Myocardial Infarction [TIMI] flow grade #1 not due to
dissection or high-grade residual stenosis adjacent to the
target lesion); acute occlusion (defined as new angiographic
occlusion within 24 h); subacute occlusion (defined as new
in-hospital angiographic occlusion more than 24 h after the
procedure). Clinical complications included blood transfu-
sion, vascular repair (by ultrasound compression or surgery),
renal failure (defined as a rise in baseline creatinine .25%),
serious arrhythmia (ventricular tachycardia, ventricular fi-
brillation or heart block requiring treatment), Q-wave MI
(defined as new Q-waves on the electrocardiogram and
elevated creatine kinase) and non–Q-wave MI (defined as
elevation of creatine kinase .3 times the upper limit of
normal in the absence of pathological Q-waves). Angio-
graphic restenosis was defined as target lesion diameter
stenosis .50% at follow-up angiography.
Statistical analysis. Categorical variables were expressed as
frequencies and continuous variables as mean 6 SD. Pre-
dictors of late outcome were determined by univariate
logistic regression analysis. The 20 covariates with a univar-
iate p value ,0.07 were entered into the Cox proportional
hazard model. The covariates were: recurrent angina, prior
MI, age of SVG, stent, congestive heart failure (CHF),
gender, hypertension, hypercholesterolemia, slow flow,
smoking, multiple stents, IABP, diabetes, peripheral vascu-
lar disease (PVD), unstable angina, restenosis, number of
diseased vessels, arrhythmias, left ventricular ejection frac-
tion and age of patient. A step-down analysis was performed
until only those variables with p , 0.05 were in the final
model. The stent variable was kept in until the last step even
if it was not significant. Late total and event-free survival
analysis for all patients was performed using the Kaplan-
Meier method, including: 1) freedom from death (total
survival), 2) freedom from death and nonfatal MI (infarct-
free survival), 3) freedom from death, nonfatal MI and
CABG (infarct and CABG-free survival), and 4) freedom
from death, nonfatal MI, CABG and target vessel revascu-
larization (event-free survival). Event-free survival was also
determined for subgroups of patients with and without
stents. A p value ,0.05 was considered statistically signif-
icant.
RESULTS
Patient characteristics. The study population included
1,062 patients with a mean age of 67 6 8 years. Baseline
demographic and clinical characteristics are described in
Table 1. The mean age of the SVGs was 9.1 6 5 years.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CHF 5 congestive heart failure
IABP 5 intra-aortic balloon pump
MACE 5 major adverse cardiac event
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
PVD 5 peripheral vascular disease
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis In Myocardial Infarction
Table 1. Characteristics of 1,062 Patients
Clinical characteristics
Mean age (yr) (mean 6 SD) 67 6 8
Men/women 817/245
Previous MI 634 (60%)
Restenotic lesion 172 (16%)
History of PVD 260 (24%)
History of CHF 160 (15%)
Diabetes 408 (38%)
Hypertension 739 (70%)
Hypercholesterolemia 698 (66%)
Smoking 172 (16%)
Indications for revascularization
Acute-MI 64 (6%)
Post-MI 117 (11%)
Stable angina 170 (16%)
Unstable angina 711 (67%)
Angiographic characteristics
One-vessel disease 21 (2%)
Two-vessel disease 64 (6%)
Three-vessel disease 977 (92%)
Graft age (yr) (mean 6 SD) 9.1 6 5
LVEF (%) 42 6 11
CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; PVD 5 peripheral vascular disease.
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Indications for revascularization included stable angina in
170 patients (16%), unstable or postinfarction angina in 828
patients (78%) and acute MI in 64 patients (6%). Of the
patients, 16% had undergone previous PTCA at the site of
the stenosis.
Procedure. Percutaneous intervention was performed in
1,142 lesions, including stents in 478 lesions (42%), PTCA
alone in 483 lesions (42%) and laser or atherectomy in 181
lesions (16%) (Table 2). An IABP was placed in 91 (9%)
patients (Table 3).
Immediate results. Cardiopulmonary resuscitation was
performed during intervention in 10 (0.9%) patients; no-
reflow phenomenon and life-threatening arrhythmias oc-
curred in 90 (8%) and 67 (6%) patients, respectively (Table
3). Non–Q-wave MI occurred in 95 patients (9%). Other
complications included stroke in 6 patients (0.6%), subacute
occlusion in 8 patients (0.8%) and blood transfusion in 95
patients (9%) (Table 3). In-hospital MACE occurred in
13% of patients (Table 4). Univariate predictors of in-
hospital MACE included restenotic lesion, unstable angina
and CHF (Fig. 1). Late MACE occurred in 54% of the
patients (Table 4). Univariate predictors included PVD,
IABP placement and previous MI; multivariate predictors
of late MACE included restenotic lesion, PVD, CHF and
placement of multiple stents (Fig. 1, Table 5).
Long-term follow-up. Clinical follow-up was available in
1,056 (99%) patients at 3 6 1 year after intervention. Late
MACE occurred in 565 patients (54%) (Table 4). Univar-
iate and multivariate predictors of late MACE are shown in
Figure 1 and Table 5. Event-free survival (freedom from
death, nonfatal MI and revascularization) is shown in
Figure 2. Within the first 200 days after the procedure, 65%
Table 2. Procedures Performed on 1,142 Saphenous Vein Grafts
No stent n 5 664 (58%)
PTCA alone 483 (42%)
DCA/PTCA 46 (4%)
ELCA/PTCA 10 (0.9%)
MRA/PTCA 34 (3%)
TEC/PTCA 91 (8%)
Stent n 5 478 (42%)*
PTCA/J&J 228 (20%)
PTCA/Biliary 114 (10%)
PTCA/Wallstent 46 (4%)
PTCA/Cook 8 (0.7%)
ELCA/Stent 6 (0.5%)
MRA/Stent 7 (0.6%)
TEC/Stent 69 (6%)
*Single stent (n 5 349, 73%), multiple stents (n 5 129, 27%).
DCA 5 directional coronary atherectomy; ELCA 5 excimer laser coronary
angioplasty; J&J 5 Johnson & Johnson; MRA 5 mechanical rotational atherectomy;
PTCA 5 percutaneous transluminal coronary angioplasty; TEC 5 transluminal
extraction atherectomy.
Table 3. In-hospital Complications in 1,062 Patients
Procedural events
CPR 10 (0.9%)
IABP 91 (9%)
Arrhythmia 67 (6%)
No-reflow 90 (8%)
Other events
Non–Q-wave MI 95 (9%)
Occlusion (acute/subacute) 8 (0.8%)
Stroke 6 (0.6%)
Blood transfusion 95 (9%)
Groin hematoma 215 (20%)
Peripheral vascular repair 16 (2%)
Renal failure 34 (3%)
CPR 5 cardiopulmonary resuscitation; IABP 5 intra-aortic balloon pump; MI 5
myocardial infarction.
Table 4. Incidence of MACE in 1,056 Patients
In-hospital
Death 89 (8%)
Q-wave MI 18 (2%)
CABG 30 (3%)
Late
Death 92 (9%)
Q-wave MI 94 (9%)
TVR (PTCA and CABG) 379 (36%)
Any
MACE 457 (43%)
CABG 5 coronary artery bypass graft surgery; MACE 5 major adverse cardiac event;
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angio-
plasty; TVR 5 target vessel revascularization.
Figure 1. Univariate predictors for (A) in-hospital and (B) late major
adverse cardiac events (MACE). CHF 5 congestive heart failure; IABP 5
intra-aortic balloon pump; MI 5 myocardial infarction; PVD 5 peripheral
vascular disease; USA 5 unstable angina.
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of the late MACE occurred. The majority of these late
events (36%) were repeat revascularization procedures in-
cluding redo-CABG and percutaneous interventions. After
the first 200 days, MI and death constituted the majority of
late MACE.
A total of 422 patients (40%) underwent repeat angiog-
raphy for recurrent angina at 3.6 6 1.8 (range 1 to 9)
months after initial intervention. Of these patients who
underwent repeat angiography for clinical symptoms, 303
(72%) had angiographic evidence of either restenosis or
presence of a new lesion in the target vessel. Restenosis or
the presence of a new lesion occurred in 122 (29%) of SVGs
treated with stents and 181 (43%) of those without a stent
(p 5 0.04). Of the remaining 119 (28%) of the patients, 25
(21%) had no new lesions, 56 (47%) had new lesions in
other SVGs and 38 (32%) had new lesions in their native
coronary arteries. There was no difference in event-free
survival for patients treated with a stent compared with
those without a stent (Figs. 3 and 4).
DISCUSSION
In this study, three-year event-free survival after percutane-
ous intervention in SVGs was 47%; there was no benefit in
event-free survival for stent patients. The independent
multivariate predictors of late MACE included PVD, rest-
enotic lesion, CHF and placement of multiple stents,
suggesting that late outcome is most dependent on the
extent and progression of atherosclerosis and not the target
lesion per se.
Percutaneous transluminal coronary angioplasty of SVGs
is associated with angiographic restenosis rates as high as
68%, with a correspondingly high incidence of late cardiac
events (8,13). Although newer interventional devices such as
atherectomy and laser have been proposed as alternative
techniques to PTCA, their use is frequently associated with
angiographic complications, including distal embolization
(10,12), no-reflow (11,14), perforation, abrupt closure
(15,16) and a high incidence of MACE (17,18).
Progressive nature of vein graft disease. The attrition rate
in SVGs is dissimilar from native coronary arteries, con-
tinuing beyond six months. Most late events are attributed
to the progression of coronary artery disease elsewhere, both
in native arteries and SVGs, a process not prevented by
stenting. Continued “attrition” despite stenting is supported
by the findings in our study and is also supported by
previously published data. For example, in the randomized
Saphenous Vein De Novo trial (SAVED) (PTCA versus
Palmaz-Schatz stent) (9) and WINS (Wallstent versus
Palmaz-Schatz stent) (19) trials, 30% to 50% of late cardiac
events (after one year) were due to death, MI or revascu-
larization of sites other than the initial target lesion, which
contrasts sharply with native vessel stenting in which 90% of
late cardiac events are due to target lesion revascularization.
Although newer stent designs are now available, they only
Table 5. Multivariate Predictors for Late MACE
Any MACE RR p Value
Restenotic lesion 2.51 0.0002
Previous MI 2.10 0.007
PVD 2.10 0.007
MACE 5 major adverse cardiac events; MI 5 myocardial infarction; PVD 5
peripheral vascular disease; RR 5 relative risk.
Figure 2. Total and event-free survival for patients after percutaneous revascularization of saphenous vein grafts. Solid diamond 5 death; solid square 5
death, MI; solid triangle 5 death, MI, repeat CABG; solid circle 5 death, MI, any target vessel revascularization. CABG 5 coronary artery bypass graft
surgery; MI 5 myocardial infarction.
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modestly impact SVG interventions, mainly with respect to
stent delivery. It is unlikely that stent type will alter
long-term clinical outcome.
More than half (65%) of the MACE in our study
occurred within the first 200 days, and the remaining events
occurred incrementally over the subsequent 1,000 days. The
majority of these early events were target vessel revascular-
ization procedures and redo-CABG. The importance of the
progression of SVG disease at untreated sites and the low
event-free survival rate in patients without restenosis has
been reported by others (20). Half of the clinical events after
SVG interventions occur within the first 6 to 12 months,
the majority being related to revascularization to treat
progressive disease at different sites rather than late deteri-
oration at the stent site itself (21). A recent study evaluating
the predictors of clinical outcome in 106 patients after SVG
interventions reported a 44% event-free survival rate and a
15% death rate at 18 months (22). They found that the
Figure 3. Freedom from repeat target vessel revascularization (percutaneous and surgical revascularization) after saphenous vein graft intervention. Solid
diamond 5 stent (n 5 415); solid square 5 no stent (n 5 614). p 5 0.4.
Figure 4. Freedom from death, myocardial infarction, percutaneous revascularization or redo-bypass surgery after saphenous vein graft intervention. Solid
diamond 5 stent (n 5 415); solid square 5 no stent (n 5 614). p 5 0.2.
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presence of a high-grade lesion ($50%) in the SVG
detected by visual inspection in a patent nonstented graft
was the strongest predictor of MACE. Even in the patients
without restenosis, the event-free survival was only 29%.
Redo-CABG versus percutaneous intervention. Patients
undergoing redo-CABG have been reported to have in-
creased in-hospital mortality, decreased long-term survival
and significantly greater recurrent angina compared with
those undergoing initial CABG (4,23). Percutaneous revas-
cularization, on the other hand, has been associated with
lower procedural morbidity and mortality but less complete
revascularization and a greater need for repeat procedures
compared with both initial and redo-CABG (5,23,24).
After controlling for the major correlates of survival, one
study showed that redo-CABG resulted in equivalent over-
all survival, event-free survival and relief of angina compared
with percutaneous intervention (7). These studies indicate
that, in patients who have undergone CABG, the principal
determinant of survival is the extent and rate of progression
of underlying coronary artery disease and that all modalities
of revascularization are primarily palliative in nature (25).
Our data is consistent with these findings in that stents,
despite reducing restenosis and procedural morbidity in
SVGs, do not improve event-free survival.
Recent advances in SVG interventions. Although not yet
published, results of the Saphenous Vein Graft Angioplasty
Free of Emboli Randomized (SAFER) trial (26) indicate an
improvement in TIMI 3 flow, a decrease in no-reflow and
a 50% to 60% reduction in 30-day MACE in patients
undergoing vein graft stenting with the Guardwire (Percu-
Surge, Inc., Sunnyvale, California) (27). This device was not
available during the course of our study and is presently not
a standard of care during SVG interventions. It is uncertain
as to whether its use will alter long-term outcome. Although
several studies have demonstrated little or no impact on
clinical end points with the use of the IIb/IIIa inhibitor
abciximab, some report modest benefit in thrombus score
(28–30). It is unclear as to whether the use of IIb/IIIa
inhibitors are beneficial in decreasing in-hospital MACE
(31); whether they will impact the long-term results of SVG
interventions remains to be seen.
Study limitations. This study has several important limi-
tations: 1) it is a retrospective and nonrandomized observa-
tional study, 2) its results may be skewed by the procedural
preferences and patient population seen at our institution,
and 3) routine angiographic follow-up was not obtained;
therefore, we cannot distinguish between target lesion
revascularization and target vessel revascularization.
Conclusions. This study shows that, despite the use of new
interventional devices including stents, patients who un-
dergo percutaneous revascularization procedures for SVG
disease have significant morbidity and mortality within the
first year. Although stent implantation was associated with
less restenosis, it was not associated with better event-free
survival. Progressive disease at nontreated sites in the SVG
or in the native coronary arteries may be an important factor
leading to cardiac events after stent implantation.
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